Chimerix, Inc.

310 articles about Chimerix, Inc.

• Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada

  6/24/2022

  Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Public Health Agency of Canada awarded Chimerix a contract up to $25.3 million agreement to procure TEMBEXA®.

• Chimerix Announces $9.3 Million International TEMBEXA Procurement Agreement

  6/23/2022

  Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced a $9.3 million agreement to procure TEMBEXA ® (brincidofovir) with a third party outside of North America, with authorization from the requisite healthcare authority.

• Chimerix to Present at Jefferies Global Healthcare Conference - June 01, 2022

  6/1/2022

  Chimerix announced that Mike Sherman, Chief Executive Officer, will present a corporate overview at the upcoming Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 3:30 p.m. in New York City.

• Chimerix to Present at H.C. Wainwright Global Investment Conference

  5/17/2022

  Chimerix announced that Mike Sherman, Chief Executive Officer, will present a pre-recorded corporate presentation at the H.C. Wainwright Global Investment Conference made available on Tuesday, May 24, 2022 at 7:00 a.m. ET.

• Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

  5/16/2022

  Emergent BioSolutions Inc. announced that it has entered into a definitive agreement with Chimerix, Inc., to acquire Chimerix’s exclusive worldwide rights to TEMBEXA®, the first antiviral approved by the U.S. Food and Drug Administration for all age groups for the treatment of smallpox.

• Chimerix Reports First Quarter 2022 Financial Results and Provides Operational Update

  5/16/2022

  Chimerix reported financial results for the first quarter ended March 31, 2022 and provided an operational update.

• Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties

  5/16/2022

  Chimerix announces it has entered into a definitive agreement with Emergent BioSolutions Inc. to acquire its exclusive worldwide rights to brincidofovir, including TEMBEXA®.

• Chimerix to Participate in Maxim Group Panel Discussion

  5/12/2022

  Chimerix announced that Josh Allen, Ph.D., Chief Technology Officer of Imipridones, will participate in a panel discussion hosted by Maxim Group.

• Chimerix to Report First Quarter 2022 Financial Results and Provide an Operational Update on May 16, 2022

  5/9/2022

  Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Monday, May 16, 2022 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2022, and to provide a business overview.

• Chimerix to Present at Maxim Group 2022 Virtual Growth Conference

  3/21/2022

  Chimerix today announced that Mike Sherman, Chief Executive Officer, will present a pre-recorded presentation at the Maxim Group 2022 Virtual Growth Conference taking place March 28-30, 2022.

• Chimerix Reports Fourth Quarter and Year End 2021 Financial Results and Provides Operational Update

  3/1/2022

  Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2021 and provided an operational update.

• Chimerix to Present at Cowen and Company 42nd Annual Health Care Conference

  2/28/2022

  Chimerix announced that Mike Sherman, Chief Executive Officer and Mike Andriole, Chief Financial and Business Officer, will participate in a fireside chat at the Cowen and Company 42nd Annual Health Care Conference on Monday, March 7, 2022 at 12:50 p.m. ET.

• Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative (READDI) at the University of North Carolina-Chapel Hill, Announces Late-Breaking Oral Presentation at International Conference on Antiviral Research

  2/24/2022

  Chimerix announced that preclinical data from the Company’s CMX521 program will be featured in a late-breaking oral presentation session at the International Conference on Antiviral Research on Wednesday, March 23, 2022 from 12:15 – 1:00 pm PT.

• Chimerix to Report Fourth Quarter and Year End 2021 Financial Results and Provide an Operational Update on March 1, 2022

  2/22/2022

  Chimerix today announced that it will host a live conference call and audio webcast on Tuesday, March 1, 2022 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2021, and to provide a business overview.

• Chimerix to Present at B. Riley Virtual Oncology Conference

  1/20/2022

  Chimerix announced Mike Andriole, Chief Business and Financial Officer, will present a corporate overview at the B. Riley Virtual Oncology Conference on Thursday, January 27, 2022 at 3:00 p.m. ET.

• Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research

  1/18/2022

  Chimerix today announced that a peer-reviewed article entitled, “Phase 2 Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma (PC-PG) and Desmoplastic Small Round Cell Tumor (DSRCT),” has been published in the journal, Clinical Cancer Research.

• Chimerix to Present at Virtual H.C. Wainwright BioConnect 2022 Conference

  1/3/2022

  Chimerix announced that Company management, including Mike Sherman, Chief Executive Officer, and Mike Andriole, Chief Business and Financial Officer, will participate in a pre-recorded fireside chat at the H.C. Wainwright BioConnect 2022 Conference made available on Monday, January 10, 2022 at 7:00 a.m. ET.

• Chimerix Announces Positive ONC201 Data in Recurrent H3 K27M-mutant Diffuse Midline Glioma to Be Presented at the Society for Neuro-Oncology Annual Meeting

  11/19/2021

  Chimerix today announced the presentation of positive data from its 50-patient efficacy analysis of ONC201 with a Conference Call at 8:30 a.m. ET on Monday, November 22.

• Chimerix to Present at Jefferies London Healthcare Conference

  11/12/2021

  Chimerix,a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, announced that Mike Sherman, Chief Executive Officer of Chimerix, will participate in a pre-recorded presentation at the Jefferies London Healthcare Conference that will be made available on Thursday, November 18, 2021 at 3:00 a.m. ET.

• 

  Clinical Catch-Up: November 1-5

  11/8/2021

  The first week of November was marked by numerous clinical trial announcements. Here’s a look.